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Abstract
Background: In palliative care, administration of opioids is often indispensable for pain treatment. Pain assessment
may help recognize pain and guide treatment in non-communicative patients. In the Netherlands the Rotterdam
Elderly Pain Observation Scale (REPOS) is recommended to this aim, but not yet validated. Therefore the objective
of this study was to validate the REPOS in non-communicative or unconscious end-of-life patients.
Methods: In this observational study, the primary researcher applied the REPOS, while both the researcher and a
nurse applied the Numeric Rating Scale (NRS). If possible, the patient in question applied the NRS as well. The NRS
scores were compared with the REPOS scores to determine concurrent validity. REPOS scores obtained before and
after a pain-reducing intervention were analysed to establish the scale’s sensitivity to change.
Results: A total of 183 REPOS observations in 100 patients were analysed. Almost 90% of patients had an advanced
malignancy; observations were done a median of 3 days (IQR 1 to 13) before death. Internal consistency of the
REPOS was 0.73. The Pearson product moment correlation coefficient ranged from 0.64 to 0.80 between REPOS
and NRS scores. REPOS scores declined with median 2 points (IQR 1 to 4) after a pain-reducing intervention (p <
0.001). Optimal sensitivity (0.81) and specificity (0.62) were found at cut-off score 3.
Conclusions: This study demonstrates that the REPOS has promising psychometric properties for pain assessment in
non-communicative end-of-life patients. Its application may be of additional value to relieve suffering, including pain,
in palliative care.
Keywords: pain measurement, palliative care, terminal care, hospice care, delirium, dementia, amnestic, cognitive
disorders, consciousness disorders
Background
Several studies reported that 45% to 70% of patients with
incurable cancer, either admitted to a hospice or staying
elsewhere, suffer moderate to severe pain [1–3]. Forty-five
per cent of those patients receive opioids, which are the
strongest analgesics [2, 4]. Pain levels should be accurately
assessed to guide pain treatment.
Patients’ self-report of pain is considered the “gold
standard” for pain assessment [5]. However, in the
terminal phase of life, patients may not be able to self-
report pain. To illustrate this, 68% to 83% of patients
had cognitive failure [6, 7] and 90% to 98% of patients
were drowsy or unresponsive prior to death [8–10].
Proxy pain assessment by a nurse was needed, therefore,
in 90% of patients in a palliative care unit at the day of
death [9]. Assessment of suffering, including pain, is
challenging anyway in the terminal phase, especially in
sedated patients [11].
Proxy assessment often underestimates the pain level,
with consequent risk of under treatment [12, 13]. The
risk might be lower if attention is paid to well-defined
behaviour indicative for pain. Therefore, application of
an observation scale that includes such behaviours (and
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has been validated for the target group) could be more
beneficial for non-communicative patients.
We previously developed the Rotterdam Elderly Pain
Observation Scale (REPOS, see Additional files 1, 2 and 3)
in a study among nursing home residents with speech limi-
tations caused by various disorders. The REPOS is available
in Dutch and English [14, 15]. Dutch palliative guidelines
recommended the REPOS for specific non-communicative
patient groups [16], such as persons with dementia and
intellectual disability. It proved a valid tool to measure pain
in the nursing home population, including those who could
not communicate [14]. However, the REPOS was not yet
validated for palliative patients and needed to be re-vali-
dated for this population.
Beside the REPOS several other observational pain as-
sessment tools have been developed for specific non-
communicative patients groups [17–19], but to our best
of knowledge only one of these has been validated for
end-of-life patients, the Multidimensional Objective Pain
Assessment Tool (MOPAT) [20]. This tool, published in
2011, was developed for hospice patients who are unable
to self-report pain. It was tested in a small sample of 28
alert patients and 30 non-communicative patients and
showed good internal consistency and sensitivity to
change after a pain-reducing intervention [20]. A disad-
vantage of the MOPAT, however, is that it includes
blood pressure and heart rate measurements, which are
often stopped at the end of life, as recommended in the
Liverpool Care Pathway for the dying patients [21].
In the Netherlands, the REPOS is increasingly adopted
in nursing homes and institutions for intellectually dis-
abled or non-communicative patients [15]. Hospice pa-
tients, however, may have other characteristics. They
often suffer from advanced cancer (> 90% of patients)
and are mostly bedridden. Self-report is not possible due
to their illness state (comatose, delirium or adverse ef-
fects of medication), in contrast to nursing home pa-
tients who more often have dementia. In addition, end-
of-life patients are in another emotional state and may
be extremely anxious, facing death. All these aspects
may influence experiences or expressions of pain [17].
Methods
Aim
The aim of this study was to revalidate the REPOS for
pain assessment in non-communicative or unresponsive
end-of-life patients.
Design, participants and setting
This observational study was performed in Laurens
Cadenza in Rotterdam. This is the largest palliative care
centre in the Netherlands, with 20 beds for end-of-life care
and symptom management; 200 to 250 patients are admit-
ted annually. The main admission criterion is having a life
expectancy of less than 3 months. Approximately 90% of
the patients have advanced malignant disease. The median
length of stay in 2010 was 11 days (IQR 5 to 29) and the
discharge rate was 4% [22]. Dutch palliative guidelines are
adhered to [16]. A multidisciplinary team of health care
professionals, including caregivers, nurses and elderly care
physicians specialized in palliative care, is available 24 h per
day. In addition, many volunteers provide support. Despite
a small difference in duration of admission the included
patients can be seen as representative of all patients admit-
ted to Cadenza during the year 2010 [22].
Assessment tools
The Rotterdam Elderly Pain Observations Scale (REPOS)
consists of 10 behavioural items (see Additional files 1, 2
and 3), which the observer scores as present or absent
after having observed the patient for two minutes prefera-
bly during a possible painful moment of care [14]. To
optimize inter-observer reliability, a definition chart,
which describes all 10 items in detail, and an intervention
decision tree are provided (see Additional files 1, 2 and 3).
To ascertain sufficient interrater reliability of a REPOS ob-
servation, nurses receive training including about 10 bed-
side paired observations with an experienced REPOS
observer [23, 24]. Sufficient interrater reliability is defined
as Cohen’s kappa> 0.65. A previous validation study in
nursing home residents revealed a significant difference
between painful and rest situations and a large correlation
with the PAINAD (r = .75) indicating good construct val-
idity. For nursing home residents both the sensitivity (.85)
and the specificity (.83) were optimal at a cut-off score of
3 [14]. However, as behaviour might be the result of other
emotions than pain, the observer in addition estimates the
pain intensity on a Numeric Rating Scale (NRS) from 0
(no pain) to 10 (worst possible pain). Thus, assigning an
‘NRS-observer’ score is a standard part of the REPOS
observation [15]. A REPOS score of 3 or higher in
combination with a NRS-observer score of 4 or higher
suggests moderate to severe pain for which an interven-
tion is required [14, 25]. The NRS is considered a valid
tool to assess cancer pain intensity [26, 27].
Procedure
Data were collected during three phases, based on the
implementation of REPOS and its use in standard care
in Laurens Cadenza: training, application in daily prac-
tice, and sensitivity-to-change data collection.
First, from March to October 2010, the primary investi-
gator (A.M.) trained nurses in Laurens Cadenza to assess
pain with the REPOS, since at that time symptom meas-
urement was not a standard of care. Firstly, the primary
investigator performed 10 bedside observations simultan-
eously with an experienced REPOS observer, to ascertain
sufficient interrater reliability for her. As Cohen’s kappa
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for the primary investigator was established at 0.76, she
was qualified to perform REPOS observations in this
study. November–December 2010, NRS and REPOS as-
sessments were implemented in daily practice for all non-
communicative or unresponsive patients. All trained
nurses achieved good interrater reliability with the pri-
mary investigator after 6 to 10 paired observations
(Cohen’s kappa values ranged from 0.70 to 0.78).
Second, from January 2011 to May 2012, the primary in-
vestigator or a trained nurse assigned a REPOS score and
an NRS-observer score in daily practice as standard of care.
Third, from February to June 2013, the second investi-
gator (A.B.) was called in when a patient received a
pain-reducing intervention and assigned a REPOS score
just before and at least one hour after this intervention.
These pre- and post-intervention data were used for the
sensitivity-to-change analysis.
To determine internal consistency, concurrent validity
and the optimal cut-off score, all REPOS observations
made during the three different phases were included,
with the exception that regarding the training phase only
the observations by the primary investigator were se-
lected and not those of the nurses in training. For the
sensitivity-to-change analysis only the pre- and post-
intervention data from phase three were used.
The type of pain assessment (REPOS observation or
self-report) depended on the patient’s ability to commu-
nicate. In the case of non-communicative or unrespon-
sive patients, the primary investigator assigned a REPOS
score and a NRS (NRS-observer), and also the caregiving
nurse assigned a NRS score (NRS-proxy). Communica-
tive patients reported in addition to the REPOS score an
NRS score themselves (NRS-patient).
Other variables
Demographic characteristics (age, gender, diagnoses, and
duration of admission) were extracted from the elec-
tronic medical records; the primary diagnoses and the
number of comorbidities were evaluated. The primary
diagnoses refer to the WHO’s International Classifica-
tion of Diseases (ICD-10 classification) coding for the
patient’s terminal illness.
Analgesics prescribed at the time of observation were
retrieved from the patients’ medical file and classified ac-
cording to the WHO three-step pain ladder as step 1
(non-opioids; acetaminophen and NSAIDs), step 2 (weak
opioids) and step 3 (strong opioids) [28, 29]. The
highest-step analgesic prescribed for a patient over all
the observations is given in the results section under the
heading patient characteristics.
Data analysis
Data are presented as mean (standard deviation; SD)
in case of normally distributed variables and as
median (interquartile range = IQR or minimum-
maximum range = range) in case of non-normally dis-
tributed variables.
To determine interrater reliability, Cohen’s kappa was
applied for the primary and second investigator and for all
nurses who assigned REPOS scores, and defined as good if
≥ 0.65 [30].
Cronbach’s alpha coefficient served to examine the
internal consistency reliability of the REPOS items; a
value of at least 0.70 is considered good reliability
[31, 32]. Pearson product moment correlation coeffi-
cient was applied to determine concurrent validity of
the REPOS with the NRS scores. This validity coeffi-
cient should exceed 0.30 [33]. The Wilcoxon signed
rank test served to estimate sensitivity to change after
a pain intervention. The optimal cut-off value for
REPOS score was determined as the best combination
of sensitivity and specificity comparing the REPOS
total scores with NRS proxy as reference.
The correlations between the REPOS, NRS proxy and
NRS observer in a repeated measurements setting were
calculated with linear mixed modelling using the method
proposed by Hamlett et al. [34]. In the linear mixed
model, we adjusted the outcomes REPOS, NRS proxy
and NRS observer for the independent variables gender,
assessment number (repeated assessments per person)
and time to death.
Data analyses were performed using IBM SPSS Statis-
tics 24. A significance level of 0.05 (two-sided) was used
for statistical tests.
Results
Patient characteristics
Over the three study phases, 194 REPOS scores were
assigned to 103 patients. Data from three patients
were excluded from analysis because these observa-
tions were not considered end-of-life assessments: one
patient had been discharged after the observations
were made and in two data had been obtained earlier
than three months before death. Data of the
remaining 100 patients were included in the analysis.
For those included patients, the first (or only) obser-
vation was done a median of 3 days (IQR 1 to 13)
before death. The median age was 77 years (IQR 67
to 85), 65% were female, and the median duration of
admission was 28 days (IQR 9 to 51). Advanced
malignancy, mainly of digestive and respiratory or-
gans, was the main reason for admission (89% of
patients). Most patients (73%) were receiving a stand-
ing dose of strong opioids combined with a rescue
prescription for breakthrough pain. Six percent of all
patients had an ‘as needed’ opioids prescription only,
and 11% received no analgesics at all. Patient charac-
teristics are shown in Table 1.
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REPOS scores and NRS scores
The number of REPOS observations for the 100
patients included in the analysis was 183. The REPOS
has been applied once in 52 patients and twice or
more (range between 2 and 13) in 46. The observa-
tions were conducted by the observer when caregivers
provided care, i.e. 34% during washing or dressing,
30% during posture change, 21% during rest, 9% dur-
ing a transfer, and 6% in other care situations.
The median REPOS score was 3 (IQR 1 to 5); the
median NRS-observer, NRS-proxy and NRS-patient
scores were 2 (IQR 0 to 4), 3 (IQR 1 to 6) and 6
(IQR 2 to 7), respectively. REPOS scores indicative of
pain (3 to 10) were assigned in 55% (101/183) of
observations. Pain was rated moderate to severe (NRS
4 to 10) in 30% to 67% of NRS scores. All 10 REPOS
items were scored as present more frequently in
association with NRS scores 4 to 10 than in associ-
ation with lower NRS scores (Table 2). The items
‘tense face’, ‘raising upper lip’ and ‘closing eyes’ were
the ones most often observed in association with NRS
scores of 4 to 10; the items ‘fearful look’ and ‘panicky’
the least often (Fig. 1).
Internal consistency
The Cronbach’s alpha coefficient for internal consistency
of the REPOS was 0.73. The item-total correlations
ranged from 0.18 to 0.69, and were below 0.30 for items:
panicky, fearful look, moaning and moving body parts.
Concurrent validity
The REPOS was correlated to the NRS-observer,
NRS-proxy and NRS-patient separately. The Pearson
product moment correlation coefficient ranged from
0.64 (95% CI 0.51 to 0.74) to 0.80 (95% CI 0.72 to
0.86) (Table 3). Linear mixed modelling revealed a
correlation between 0.64 and 0.78 for the REPOS,
NRS proxy and NRS observer corrected for gender,
assessment number (repeated assessments per person)
and time to death.
Deleting the above-mentioned 4 items with low corre-
lations for internal consistency had hardly any effect on
the Pearson coefficients, which then ranged from 0.62
(95% CI 0.49 to 0.73) to 0.80 (95% CI 0.72 to 0.86).
Sensitivity to change
Twenty-two pairs of before-and-after scores were in-
cluded for the sensitivity-to-change analysis. Twenty-one
concerned a pharmacological pain-reducing interven-
tion; the other pair concerned changing the patient’s
posture to relieve or prevent pressure sores.
The median REPOS score declined after a pain-
reducing intervention, both pharmacological and non-
pharmacological, from 4 (IQR 3 to 6) to 1 (IQR 1 to 3)
with a median reduction of 2 points (IQR 1 to 3). This
change was statistically significant (p < 0.001). The per-
centage of REPOS scores indicating no pain (score 0 to
2) increased from 9% (2/22) to 68% (15/22).
Table 1 Patient characteristics
Characteristics N = 100
Gender in %
Male / female 35 / 65
Age in years
median (IQR) 77 (67 to 85)
Duration of admission in days
Median (IQR) 28 (9 to 51)
Assessments days before death
Median (IQR) 3 (1 to 13)
Primary diagnose in N (%)
Neoplasms 89
Digestive organs 26 (29)
Respiratory and intra-thoracic
organs
17 (19)
Female genital organs 9 (10)
Breast 7 (8)
Eye, brain and other parts of
central nervous system
7 (8)
Lymphoid, hematopoietic and
related tissue
7 (8)
Ill –defined, secondary and
unspecified sites
7 (8)
Other 9 (10)
Disease of nervous system 4 (acquired brain injury; Parkinson’s
disease; systemic atrophy)
Infectious and parasitic disease 3 (pneumonia and frailty)
Other 4 (CVA; lung disease, kidney failure,
invalidity)
Analgesics in %
Opioids around the clock 73
None 11
Non-opioids around the clock 9
Opioids as needed 6
Non-opioids as need 1
Table 2 Pain assessments results
Median score
(IQR)
Moderate to severe pain
(NRS 4 to 10)
Number of observations (%)
REPOS score (N = 183) 3 (1 to 5) 101 (55)
NRS-observer (N =
182)
2 (0 to 4) 54 (30)
NRS-proxy (N = 107) 3 (1 to 6) 47 (44)
NRS-patient (N = 24) 6 (2 to 7) 16 (67)
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Cut-off score
In 107 observations, both a REPOS score and a NRS-
proxy score were available. At the cut-off REPOS
score of 3, sensitivity was 0.81 and specificity was
0.62. The ROC curve, with an AUC of 0.80 (95% CI
0.71 to 0.88), is displayed in Fig. 2. The positive
predictive value was 0.62 and the negative predictive
value was 0.80.
In 21% (23/107) of observations the REPOS score
was indicative for pain (score 3–10) whereas the
NRS-proxy score was not; suggesting false-positive
outcomes of the REPOS. In contrast, in 8% (9/107) of
observations the REPOS score did not indicate pain
(score 0–2) whereas the NRS-proxy score did (score
4–10), suggesting false-negative outcomes.
Discussion
The findings from this study show that the REPOS has
promising psychometric properties to assess pain in
non-communicative end-of-life patients; including ad-
equate internal consistency, sufficient concurrent validity
and good sensitivity to change after a pain-reducing
intervention.
A variety of observational pain scales have been devel-
oped for other settings where non-communicative pa-
tients are treated, including intensive care units [35] and
nursing homes [19]. Only one, the MOPAT [20], has
been validated for non-communicative end-of-life pa-
tients, albeit preliminary and without establishing a cut-
off score. The MOPAT was published after start of our
study (2010). We therefore could not use it, although it
would have been interesting to compare the two scales.
The overall internal consistency of the REPOS in the
present study was adequate as judged from the Cron-
bach’s alpha coefficient of 0.73 [31, 32]. Although the
item-total correlations of 4 items (panicky, fearful look,
moaning and moving body parts) were below 0.30, we
chose to retain those items. These low values could be
related to infrequent occurrence of those behaviours in
terminally ill patients as they receive high doses of
strong analgesics and/or sedatives. For example, the abil-
ity to fully react with all body parts is often diminished
in the end-of-life stage. In other non-communicative pa-
tients who use lower doses analgesics those behaviours
might be more obvious. In observations of nursing home
residents during a possible painful situation, i.e. washing
and clothing or during physiotherapy, when manipula-
tion irritates already affected tissue (i.e. arthritis) all 10
behaviours were seen. Deletion of those 4 items could
therefore create a risk of underestimating pain in a
broader group of non-communicative patients. The
major reason for retaining these items is that the scale
should be applicable in other settings with non-
communicative patients as well.
With respect to concurrent validity, a high correlation
(0.73) was found – not surprisingly – between REPOS
and NRS scores assigned by the same person. The correl-
ation between REPOS and the gold standard (NRS-pa-
tient) was only moderate [32], as is seen in other pain
scale studies too [36, 37]. This moderate correlation is
Fig. 1 Percentage of scored REPOS items for no-mild pain and for
moderate-to-severe pain
Table 3 Correlation between REPOS score and the various NRS
scores
REPOS
score
NRS-observer NRS-proxy NRS-patient
REPOS
score
Number of
observations
183 182 107 24
R – 0.73 0.64 0.66
95% CI – 0.65 to 0.79 0.51 to
0.74
0.35 to 0.84
NRS-
observer
Number of
observations
182 107 24
R – 0.80 0.77
95% CI – 0.72 to
0.86
0.53 to 0.90
NRS-
proxy
Number of
observations
107 24
R – 0.72
95% CI – 0.45 to 0.87
NRS-
patient
Number of
observations
24
R –
95% CI –
Note. Abbreviations: REPOS Rotterdam Elderly Pain Observation Scale, NRS
Numeric Rating Scale, R Pearson correlation, Cl Confidence Interval
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perhaps explained by patient characteristics. Patients who
are unable to report pain with the NRS seem to show
more nonverbal behaviour, such as grimace [36, 38]. For
these patients their pain would be better reflected by a be-
havioural score than by a proxy NRS only.
It is not unexpected that the REPOS score and the
NRS-proxy score may differ to some extent. A high
REPOS score combined with a lower NRS-proxy score,
or a so-called false positive score, is typically seen in pa-
tients who show “emotional” behaviour not related to
pain, but based on anger, fear or agitation [39, 40]. The
opposite, a false-negative score, may occur when the at-
tending nurse has observed behaviour not included in
the REPOS score, such as muscle tension. Alternatively,
the nurse’s NRS score reflects knowledge of relevant
characteristics, such as history or medication use, illness
and other patient specific characteristics [12, 13, 41].
This study showed that the cut-off score of 3 or higher
is applicable for non-communicative end-of-life patients.
However, application of a ‘one-fits-all’ cut-off score is de-
bated [42, 43]. A reason suggested in literature is that
different underlying conditions cause different types of
damage to the brain, and consequently different respon-
siveness to pain [43–45]. Based on these arguments one
could consider the use of an individualized cut-off score,
which has been recommended for other vulnerable pa-
tients groups, e.g. young children [46]. However, this ap-
proach asks more from the caregivers: it is a dynamic
approach requiring evaluation and adjustment at regular
times and when indicated. As daily pain assessment itself
was shown to be problematic [47], one can wonder if an
individualized approach is feasible in a daily care situ-
ation [48, 49].
A strength of the present study is that most observa-
tions were done within the last two weeks of life and
therefore including even those patients near the time of
death. In the previous validation study of the REPOS [14],
only a small proportion of the population was at the end
of life. In addition, communicative patients rated their
pain themselves, which enabled comparison between the
REPOS and the gold standard of self-report. Also, the
sample size in the present study was 100 patients, which
far exceeds the minimal number of 50 patients [31, 50].
Some limitations of this study have to be addressed, how-
ever. First, this is a single-centre study in mainly advanced
cancer patients and care must be exercised in extrapolating
the findings to other settings and patients populations, like
palliative home care or community-based palliative care.
Nevertheless, it seems unlikely that pain behaviour would
be different in a different palliative environment. Second,
the sensitivity-to-change analysis concerned only a rela-
tively small sample. This limitation is encountered in many
other psychometric studies, seeing that researchers often
are not available when patients receive additional analgesia
and also because nurses may tend to forego reassessment
after a pain-reducing intervention [51]. The comparable
Fig. 2 ROC curve of the optimal sensitivity and specificity for the REPOS score. The full line represents sensitivity and specificity of de REPOS
score. The dotted line represents the line for which sensitivity and specificity are equal. A horizontal and a vertical grey line are added to show
the optimal cut-off value of the REPOS score
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MOPAT study [20] also included fewer patients than
planned, mainly due to logistical reasons. The fact that the
observer knew whether the patient received pain medica-
tion or not, could be considered a weakness of the
sensitivity-to-change analysis. In the ideal situation, ob-
servers blinded for this condition apply the REPOS when
watching video recordings made before and after an inter-
vention. However, it was felt undesirable to ask relatives’ ap-
proval to film their loved ones in the dying phase for
research purposes. Still, knowing that the REPOS is sensi-
tive enough to measure small changes after an intervention
means that it is suitable for pharmacodynamic studies,
which are urgently needed in this palliative patient group
[11]. Lastly, in the present study the REPOS was compared
with NRS scores, although a comparison with another be-
haviour pain scale would have strengthened the reliability
and validity testing [52]. In future studies the outcomes of
different observational scales like the PACSLAC, PAINAD
and MOPAT should be compared and the possibility
should be explored if blinded observation is possible.
Conclusions
In conclusion, the REPOS seems to meet the criteria for
the use of a pain measurement tool in palliative care of the
Expert Working Group of the European Association of
Palliative Care (EAPC) [53]. That is, the brevity of the
scale (10 well-defined behaviors, scored yes/no after a two-
minute observation period) and the cut-off score increases
clinical utility. The scale was validated for nursing home
residents with speech limitations and the present study in-
creases the psychometric knowledge about sensitivity to
treatment effect and reliability during palliative care. The
fact that the REPOS is available in Dutch as well as English
can be seen as an advantage as well. In addition, next to
the Dutch palliative guidelines [16], the use of the REPOS
for pain assessment in non-communicative patients is rec-
ommended in a report on quality indicators in palliative
care, published by the Netherlands Institute for Health
Services Research [54]. We have demonstrated that the
REPOS seems a valid tool for the assessment of pain in
non-communicative end-of-life patients. We recommend
its use on a daily basis for every non-communicative pal-
liative patient. After a brief training course every profes-
sional palliative caregiver will be able to use it in daily
practice. A REPOS electronic educational module is avail-
able (both in Dutch or English) to guide implementation
and training [15].
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